Molecules with specificity for CD79 and CD22
US11261252B2 · kind B2 · utility
1Cited by
97References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 16, 2019 |
| Grant date | Mar 1, 2022 |
| Priority date | — |
| Expiry date | Jul 16, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.